FDA Regulation of Artificial Intelligence/ Machine Learning

In this webinar We will discuss the current regulatory requirements, how they don’t control AI/ML adequately, and approaches FDA is considering for regulation in the near future. Your development program should conform to these concepts now because, with some modifications, they will probably become regulations.

Edwin Waldbusser
Instructor:
Edwin Waldbusser
Date:
Thursday, October 29, 2020
Time:
10:00 AM PDT | 01:00 PM EDT
Duration:
60 Minutes

More Trainings by this Expert   Product Id : 503388

Price Details
$150 Live
$290 Corporate Live
$190 Recorded
$390 Corporate Recorded
Combo Offers
Live + Recorded
$289 $340 Live + Recorded
Corporate (Live + Recorded)
$599 $680 Corporate
(Live + Recorded)
Price Detail Options
Overview:

AI/ ML will revolutionize medicine by making diagnosis and treatment more accessible and more effective.

FDA has regulated medical software by means of regulation and guidance's for years, however, AI/ML programs fall outside the scope of these regulations and guidance's.

This happens because FDA approves the final, validated version of the software. The point of AI/ML is to learn and update following deployment to improve performance. Thus the field version of the software is no longer the validated approved version.

We will discuss the current regulatory requirements, how they don’t control AI/ML adequately, and approaches FDA is considering for regulation in the near future. Your development program should conform to these concepts now because, with some modifications, they will probably become regulations.

Following discussion of possible future regulation, we will discuss, based on recently approved De Novo applications, how to get your AI/ML program approved now. Necessary submission documentation will be explained.

This webinar is not a programming course but will explain the present and future regulatory requirements for AI/ML.

Why you should Attend: It is not clear how to get AI/ML programs approved. The current regulatory requirements don’t control AI/ML adequately.

We will discuss the approaches FDA is considering for regulation in the near future and how to get your AI/ML program approved by FDA now.

Necessary submission documentation will be explained Attendees will receive a multipage outline and checklist.

Areas Covered in the Session:

  • Total product life cycle approach to AI/ ML design
  • Application of FDA software Pre Cert program to AI/ ML
  • FDA discussion paper on AI/ML
  • Database management
  • QC of datasets
  • Algorithm updating
  • Reference standard development
  • Standalone performance testing
  • Clinical performance testing
  • Data enrichment
  • Emphasis on "explainability"
  • Additional labeling requirements
  • Cybersecurity

Who Will Benefit:
  • Software Engineers
  • Engineers
  • Regulatory personnel
  • Quality Assurance personnel
  • Marketing
  • Management


Speaker Profile
Edwin Waldbusser is a consultant retired from industry after 20 years in management of development of medical devices (5 patents). He has been consulting in the US and internationally in the areas of design control, risk analysis and software validation for the past 8 years. Mr. Waldbusser has a BS in Mechanical Engineering and an MBA. He is a Lloyds of London certified ISO 9000 Lead Auditor and a member of the Thomson Reuters Expert Witness network.


You Recently Viewed